Researchers found that an at-home self-collection device for HPV testing demonstrated high accuracy and safety, matching clinician-collected results for cervical cancer screening.
The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.